1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. dPCR & qPCR Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of infectious diseases and genetic disorders
5.1.1.2. Increasing usage of dPCR and qPCR for efficient delivery of personalized medicine
5.1.1.3. Improving adoption in food testing procedures to ensure safety and consumption
5.1.2. Restraints
5.1.2.1. High cost associated with dPCR and qPCR
5.1.3. Opportunities
5.1.3.1. Technological advancements in PCR technologies
5.1.3.2. Growing funding for genomics research projects worldwide
5.1.4. Challenges
5.1.4.1. Technical limitations and data analysis complexities associated with dPCR and qPCR techniques
5.2. Market Segmentation Analysis
5.2.1. Product: Expanding presence of sophisticated PCR instruments for rapid detection of genetic sequences
5.2.2. Application: Utilization of dPCR and qPCR in clinical applications for infection monitoring and detection
5.2.3. End-user: Rising focus of academic research and academic institutes toward PCR technologies
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. dPCR & qPCR Market, by Product
6.1. Introduction
6.2. Instruments
6.3. Reagents & Consumables
6.4. Software & Services
7. dPCR & qPCR Market, by Application
7.1. Introduction
7.2. Clinical Application
7.3.1. Blood Screening
7.3.2. Oncology Testing
7.3.3. Pathogen Testing
7.3. Forensic Applications
7.4. Research Application
8. dPCR & qPCR Market, by End-User
8.1. Introduction
8.2. Academic Research & Institutes
8.3. Contract Research Organizations
8.4. Hospitals & Care Providers
8.5. Pharmaceutical & Biotechnology Companies
9. Americas dPCR & qPCR Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific dPCR & qPCR Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa dPCR & qPCR Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Agreement, Collaboration, & Partnership
12.3.1.1. Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
12.3.2. New Product Launch & Enhancement
12.3.2.1. QIAGEN Expands Range of Digital PCR Kits and Services for the Biopharma Industry
12.3.2.2. Thermo Fisher Scientific Launches New Digital PCR Automation Solution
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. 10x Genomics, Inc.
13.1.2. Abbott Laboratories
13.1.3. accela s.r.o.
13.1.4. Agilent Technologies, Inc.
13.1.5. Analytik Jena GmbH
13.1.6. Becton Dickinson and Company
13.1.7. Bio-Rad Laboratories, Inc.
13.1.8. BioMed Central Ltd
13.1.9. BioMérieux S.A.
13.1.10. Canopy Biosciences, LLC
13.1.11. Combinati Inc.
13.1.12. Danaher Corporation
13.1.13. F. Hoffman-La Roche Ltd.
13.1.14. GE Healthcare Inc.
13.1.15. JN Medsys Pte. Ltd.
13.1.16. Merck KGaA
13.1.17. PerkinElmer, Inc.
13.1.18. Pfizer Inc.
13.1.19. Promega Corporation
13.1.20. QIAGEN N.V. by Thermo Fisher Scientific, Inc.
13.1.21. Roche Holding AG
13.1.22. Siemens Healthineers AG
13.1.23. Stilla Technologies SA
13.1.24. Takara Bio Inc.
13.1.25. Vela Diagnostics
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing